Türk Kardiyomiyopati Hastalarında Hipertrofik Kardiyomiyopati ile İlişkili Gen Paneli Kullanılarak Genotip ve Fenotip Analizi Yapılması

Öz

Giriş ve Amaç: Hipertrofik kardiyomiyopati (HCM), sarkomerik proteinlerdeki mutasyonların neden olduğu ve kalp kasının hipertrofisi ile karakterize otozomal dominant bir hastalıktır. Gereç ve Yöntemler: Bu çalışmada, 21 HCM hastası ve bazılarının ebeveynleri, 17 genden oluşan hedeflenmiş bir panel kullanılarak yeni nesil dizileme aracılığıyla değerlendirilmiştir. Bulgular: 6 hastada, MYH7 (p.R663C, p.A423V), MYBPC3 (p.P955fs*95, p.K301fs*31), TNNT2 (p.R154Q) ve TNNI3 (p.R204C) genlerinde patojenik veya yüksek olasılıkla patojenik varyantlar tespit edilmiştir. Sonuç: Klinik bulgular literatür ile karşılaştırılarak bu varyantların genotip-fenotip korelasyonları tartışıldı. TNNI3 genindeki p.R204C varyantının literatürde ilk kez restriktif kardiyomiyopatiye neden olduğu saptanmıştır

Anahtar Kelimeler

• Hipertrofik kardiyomiyopati
• MYH7
• MYBPC3
• TNNT2
• TNNI3

Genotype and Phenotype Analysis Using a Hypertrophic Cardiomyopathy-Associated Gene Panel in Turkish Cardiomyopathy Patients

Öz

Objective: Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disorder caused by mutations in sarcomeric proteins and characterized by hypertrophy of the heart muscle. Materials and Methods: In the present study, 21 patients with HCM and some of their parents were evaluated via next-generation sequencing (NGS) using a targeted panel of 17 genes. Results: Pathogenic or likely pathogenic variants were detected in six patients in the genes MYH7 (p.R663C, p.A423V), MYBPC3 (p.P955fs*95, p.K301fs*31), TNNT2 (p.R154Q), and TNNI3 (p.R204C). Conclusion: The genotype-phenotype correlations of these variants were discussed by comparing the clinical findings with the literature. p.R204C variant in the TNNI3 gene was found to be caused restrictive cardiomyopathy for the first time in the literature.

Anahtar Kelimeler

• Hypertrophic cardiomyopathy
• MYH7
• MYBPC3
• TNNT2
• TNNI3

Kaynakça

1. Marian, A.J, Braunwald, E, Hypertrophic Cardiomyopathy, Circulation Research, 2017, 121, 749–70.
2. Familial hypertrophic cardiomyopathy: MedlinePlus Genetics n.d. https://medlineplus.gov/genetics/condition/familial-hypertrophic-cardiomyopathy/ (accessed July 16, 2021).
3. Branzi, A, Romeo, G, Specchia, S, et al., Genetic heterogeneity of hypertrophic cardiomyopathy, International Journal of Cardiology, 1985, 7, 129–33.
4. Kaski, J.P, Syrris, P, Esteban, M.T.T, et al., Prevalence of Sarcomere Protein Gene Mutations in Preadolescent Children With Hypertrophic Cardiomyopathy, Circulation: Cardiovascular Genetics, 2009, 2, 436–41.
5. Kimura. A, Harada. H, Park.. J-E, et al., Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy, Nature Genetics, 1997, 16, 379–82.
6. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle | Nature Genetics n.d. https://www.nature.com/articles/ng0596-63 (accessed July 16, 2021).
7. Samsunlu, E.T, GEN TERAPİSİNDE CRISPR-CAS9, Celal Bayar University Journal of Science, 2021.
8. Pradeep, R, Akram, A, Proute, M.C, et al., Understanding the Genetic and Molecular Basis of Familial Hypertrophic Cardiomyopathy and the Current Trends in Gene Therapy for Its Management, Cureus, 2021,13.

9. Daehmlow, S, Erdmann, J, Knueppel, T, et al., Novel mutations in sarcomeric protein genes in dilated cardiomyopathy, Biochemical and Biophysical Research Communications, 2002, 298, 116–20.
10. Dong, X, Fan, P, Tian, T, et al., Recent advancements in the molecular genetics of left ventricular noncompaction cardiomyopathy, Clinica Chimica Acta, 2017, 465, 40–4.
11. Bashyam, M.D, Savithri, G.R, Kumar, M.S, Narasimhan, C, Nallari, P, Molecular genetics of familial hypertrophic cardiomyopathy (FHC), Journal of Human Genetics, 2003, 48, 55–64.
12. Armel, T.Z, Leinwand, L.A, Mutations in the beta-myosin rod cause myosin storage myopathy via multiple mechanisms, Proceedings of the National Academy of Sciences, U S A 2009, 106, 6291–6.
13. Seidman, C, Hypertrophic cardiomyopathy: from man to mouse, The Journal of Clinical Investigation 2000, 106.
14. Christiaans, I, Nannenberg, E.A, Dooijes, D, et al., Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands, Netherlands Heart Journal, 2010,18,248–54.
15. Probst, S, Oechslin, E, Schuler, P, et al., Sarcomere gene mutations in isolated left ventricular noncompaction cardiomyopathy do not predict clinical phenotype, Circulation: Cardiovascular Genetics, 2011, 4, 367–74.
16. Daehmlow, S, Erdmann, J, Knueppel, T, et al., Novel mutations in sarcomeric protein genes in dilated cardiomyopathy, Biochemical and Biophysical Research Communications, 2002, 298, 116–20.
17. Charron, P, Dubourg, O, Desnos, M, et al., Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene, Circulation, 1998, 97, 2230–6.
18. Hershberger, R.E, Norton, N, Morales, A, L,i D, Siegfried, J.D, Gonzalez-Quintana, J, Coding sequence rare variants identified in MYBPC3, MYH6, TPM1, TNNC1, and TNNI3 from 312 patients with familial or idiopathic dilated cardiomyopathy, Circulation: Cardiovascular Genetics, 2010, 3, 155–61.
19. Nguyen, S, Siu, R, Dewey, S, Cui, Z, Gomes, A.V, Amino Acid Changes at Arginine 204 of Troponin I Result in Increased Calcium Sensitivity of Force Development, Frontiers in Physiology, 2016, 7, 520.
20. Rani, D.S, Dhandapany, P.S, Nallari, P, Narasimhan, C, Thangaraj, K, A Novel Arginine to Tryptophan (R144W) Mutation in Troponin T (cTnT) Gene in an Indian Multigenerational Family with Dilated Cardiomyopathy (FDCM), PLOS ONE, 2014, 9, e101451.